Clinical Trials
3 trialsNCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT04985721 2023-03-15
IMPARP-HRD
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05241132 2022-02-15
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
Phase 2 Unknown